- Home
- XERS vs ALVO Comparison
XERS vs ALVO Comparison
Compare XERS & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | ALVO |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | XERS | ALVO |
|---|---|---|
| Price | $6.28 | $3.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $10.83 | $8.00 |
| AVG Volume (30 Days) | ★ 1.2M | 309.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | $13.28 |
| Revenue Next Year | $22.86 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $3.03 |
| 52 Week High | $10.08 | $11.85 |
Technical Indicators
Market Signals| Indicator | XERS | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 51.14 |
| Support Level | $6.26 | $3.03 |
| Resistance Level | $6.41 | $3.93 |
| Average True Range (ATR) | 0.20 | 0.16 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 71.38 | 57.88 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.